

Bidziński Mariusz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9463795/publications.pdf>

Version: 2024-02-01

54
papers

3,814
citations

304743

22
h-index

168389

53
g-index

55
all docs

55
docs citations

55
times ranked

7281
citing authors

#	ARTICLE	IF	CITATIONS
1	CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma. <i>Journal of Clinical Pathology</i> , 2022, 75, 324-332.	2.0	9
2	Contemporary principles of diagnostic and therapeutic management in cervical and ovarian neuroendocrine tumors. <i>Ginekologia Polska</i> , 2021, 92, 312-317.	0.7	2
3	Prognosis of the patients suffered from uterine carcinosarcoma from rural and urban areas. <i>Ginekologia Polska</i> , 2021, , .	0.7	1
4	The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 263, 139-147.	1.1	12
5	Second-line lenvatinib in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 575-582.	1.4	53
6	Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression. <i>EBioMedicine</i> , 2019, 47, 170-183.	6.1	41
7	An evaluation of the construction of the device along with the software for digital archiving, sending the data, and supporting the diagnosis of cervical cancer. <i>Wspolczesna Onkologia</i> , 2019, 23, 171-177.	1.4	1
8	Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets. <i>Gynecologic Oncology</i> , 2018, 150, 552-561.	1.4	45
9	European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 832-837.	2.5	149
10	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	10.7	1,376
11	Normalizers for microRNA quantification in plasma of patients with vulvar intraepithelial neoplasia lesions and vulvar carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831771714.	1.8	27
12	Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas. <i>JCI Insight</i> , 2017, 2, .	5.0	15
13	Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients. <i>PLoS ONE</i> , 2017, 12, e0184576.	2.5	23
14	Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer. <i>Current Gynecologic Oncology</i> , 2017, 15, 5-23.	0.1	16
15	Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of endometrial cancer. <i>Current Gynecologic Oncology</i> , 2017, 15, 34-44.	0.1	8
16	Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of vulvar cancer. <i>Current Gynecologic Oncology</i> , 2017, 15, 45-53.	0.1	1
17	Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of cervical cancer. <i>Current Gynecologic Oncology</i> , 2017, 15, 24-33.	0.1	6
18	The assessment of overall survival (OS) after adjuvant chemotherapy for patients with malignant endometrial cancer in Poland. <i>Ginekologia Polska</i> , 2017, 88, 296-301.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Trabectedin for the treatment of ovarian cancer. <i>Current Gynecologic Oncology</i> , 2017, 15, 218-223.	0.1	0
20	Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer. <i>World Journal of Surgical Oncology</i> , 2016, 14, 58.	1.9	19
21	Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 78-89.	10.7	205
22	The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease. <i>Tumor Biology</i> , 2016, 37, 1271-1278.	1.8	37
23	Laparoscopic sentinel lymph node mapping after cervical injection of indocyanine green for endometrial cancer – preliminary report. <i>Wideochirurgia I Inne Techniki Maloinwazyjne</i> , 2015, 3, 406-412.	0.7	6
24	Uterine tumors resembling ovarian sex cord tumors, a clinicopathologic study of six cases. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 329-332.	1.3	21
25	microRNAs in uterine sarcomas and mixed epithelial–mesenchymal uterine tumors: a preliminary report. <i>Tumor Biology</i> , 2013, 34, 2153-2160.	1.8	28
26	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
27	Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO–The MIMOSA Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 1554-1561.	1.6	126
28	Recommendations of Polish Gynecological Oncology Society concerning epithelial tumors of the ovary: ovarian cancer and borderline tumors. <i>Current Gynecologic Oncology</i> , 2013, 11, 9-23.	0.1	2
29	Contraception for cancer survivors. <i>Ginekologia Polska</i> , 2013, 84, 955-8.	0.7	2
30	Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3841-3847.	1.6	110
31	Identification of suitable reference genes for gene expression measurement in uterine sarcoma and carcinosarcoma tumors. <i>Clinical Biochemistry</i> , 2012, 45, 368-371.	1.9	10
32	The quality of life of women treated for cervical cancer. <i>European Journal of Oncology Nursing</i> , 2012, 16, 59-63.	2.1	28
33	High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations. <i>Cancer Genetics</i> , 2012, 205, 94-100.	0.4	19
34	Estimation of groin recurrence risk in patients with squamous cell vulvar carcinoma by the assessment of marker gene expression in the lymph nodes. <i>BMC Cancer</i> , 2012, 12, 223.	2.6	11
35	Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancers. <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 1513-1519.	1.7	9
36	The promoter methylation and expression of the O6-methylguanine-DNA methyltransferase gene in uterine sarcoma and carcinosarcoma. <i>Oncology Letters</i> , 2012, 4, 551-555.	1.8	6

#	ARTICLE	IF	CITATIONS
37	Lack of microsatellite instability in squamous cell vulvar carcinoma. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2012, 91, 391-394.	2.8	7
38	PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. <i>Human Pathology</i> , 2011, 42, 1710-1719.	2.0	51
39	Evaluation of intraoperative and postoperative complications related to lymphadenectomy in ovarian cancer patients. <i>Oncology Letters</i> , 2011, 2, 537-541.	1.8	7
40	Clinical Significance of Serum CA-125 and Soluble Tumor Necrosis Factor Receptor Type I in Cervical Adenocarcinoma Patients. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 588-592.	2.5	18
41	The Frequency of Human Papillomavirus Infection in Polish Patients With Vulvar Squamous Cell Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 434-437.	2.5	13
42	The accuracy of the sentinel lymph node concept in early stage squamous cell vulvar carcinoma. <i>Gynecologic Oncology</i> , 2010, 116, 473-477.	1.4	45
43	Gene therapy of locally advanced vulvar cancer with psFLT construct. <i>Wspolczesna Onkologia</i> , 2010, 1, 11-14.	1.4	0
44	Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3107-3114.	1.6	371
45	Comparison of cytogenetic changes between primary and relapsed patients with borderline tumors of the ovary. <i>Cancer Genetics and Cytogenetics</i> , 2009, 195, 157-163.	1.0	2
46	Early Cervical Cancer Managed by Laparoscopy and Conventional Surgery. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1390-1395.	2.5	47
47	Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival. <i>Gynecologic Oncology</i> , 2008, 109, 174-181.	1.4	104
48	TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study. <i>BMC Cancer</i> , 2008, 8, 27.	2.6	26
49	CHFR gene is neither mutated nor hypermethylated in ovarian cancer. <i>Cancer Detection and Prevention</i> , 2007, 31, 257-261.	2.1	6
50	Nadroparine activated fibrinolysis and improvement of glomerular filtration rate in patients with FIGO IIB–IIIB cervical cancer treated with radiochemotherapy. <i>Gynecologic Oncology</i> , 2007, 104, 24-31.	1.4	1
51	Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 361-371.	2.5	32
52	Detection of carbonic anhydrase 9-expressing tumor cells in the lymph nodes of vulvar carcinoma patients by RT-PCR. <i>International Journal of Cancer</i> , 2005, 116, 957-962.	5.1	24
53	Increased cancer risk of heterozygotes with NBS1 germline mutations in poland. <i>International Journal of Cancer</i> , 2004, 111, 67-71.	5.1	118
54	Laparoscopic Ligation of the Hypogastric Artery in the Case of Bleeding in Advanced Cervical Cancer. <i>Gynecologic Oncology</i> , 2002, 84, 344-348.	1.4	18